Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer - Wikidata - awgldk - TriplyDB

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

http://www.wikidata.org/entity/Q33862890

about

Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics PSA and beyond: alternative prostate cancer biomarkers What is the Need for Prostatic Biomarkers in Prostate Cancer Management?Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.Molecular pathways and targets in prostate cancer High-calorie diet exacerbates prostate neoplasia in mice with haploinsufficiency of Pten tumor suppressor gene PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Expression of ERG protein in prostate cancer: variability and biological correlates.Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.Biomarkers for prostate cancer: present challenges and future opportunities.The oncogene ERG: a key factor in prostate cancer.Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.Molecular biomarkers to guide precision medicine in localized prostate cancer.ERG expression in prostate cancer: biological relevance and clinical implication.Ductal adenocarcinoma of the prostate: Clinical and biological profiles.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Clinical variability and molecular heterogeneity in prostate cancer.Statin use and risk of disease recurrence and death after radical prostatectomy.Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.Genomic tests to guide prostate cancer management following diagnosis.PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.Tumor features and survival after radical prostatectomy among antidiabetic drug users.PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG.The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression.PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles.The expression of AURKA is androgen regulated in castration-resistant prostate cancer.Tissue-based biomarkers in prostate cancer.SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.

P2860

Q26752510-FF347327-8798-4A72-AF7A-EAD686B893F5 Q26770646-DE57A8B8-632C-4CB4-917B-C69E0D554C21 Q26798425-007DC5B0-4ADA-44E3-BB3E-0E123EF916B2 Q28546607-7FD0C00C-AD1A-4783-A9A5-82F17321EE35 Q34302881-0623FD2C-CF05-41D8-8BC9-3B511752D028 Q34365632-3B08B60C-EE92-4849-AC62-E077B6E65430 Q35113473-F067F906-DC10-4F14-86ED-266544763489 Q35540013-9DA5B6C1-5E8F-4305-B3D1-E39D3EEA58E2 Q35608000-DAD335BD-BB1C-4FE2-BAE3-2ED13E88E732 Q35690915-4944B37B-EE61-4EE3-ABF4-C362C4A4A515 Q35944835-EF9E5778-308F-43A3-A7C9-AEA745F6235A Q35983468-21024909-AE3E-477B-97B1-5D9873527A95 Q36260616-D86DFBA1-E523-41D7-8F42-7AFD56FAD431 Q36287422-91C97FE7-4D6B-47D2-91B7-1D5B6C8B328C Q36887707-BAEC593E-747C-4BA3-AE71-6A42226829B2 Q37474443-68019E8C-138D-4994-8023-BAEB17523ABB Q38444138-A1954C98-5FCF-4B25-AA0F-29C716A46E0C Q38540198-B962BB66-2C8B-49BF-B876-4B5E0C8FEEC8 Q38644658-D2AFDEF3-DC0A-4D68-9530-DBBDAD11D01A Q38668635-9CD83C3A-C5C7-4B71-942A-005AC78B04A7 Q38681610-444A7849-F49A-4E2B-8D88-28F8037B5F33 Q38683009-525E0701-874B-4924-88BE-027D5A7E3154 Q38774228-C038ACDA-281D-4C29-853F-4C931223D4E1 Q38808811-25EB6E9C-DC64-4123-AB77-5CDBF1A35871 Q38929732-0A845CE2-497E-4D52-9E94-193A74AF152F Q38967389-C6D039BF-D2FF-4C1F-AA60-CB3996589E03 Q38980564-9D685FE1-C092-428D-AAA9-AC89FEA96589 Q39170943-652537EF-51EE-4401-A436-6436CB02FB50 Q39401816-505CEC0D-7718-4E2E-9BD4-E8E07951CCB6 Q39510855-9C1C328E-0EA8-42F0-90E9-DB0CB35435E6 Q41907553-66455497-33E1-4E1A-B00D-99F8BC7B9556 Q42173139-FF133CBA-AFE7-4E72-9FDA-3F9C528ABB6E Q42356687-15F039A1-D57B-454F-8063-8800BEB21D07 Q42782654-DDA711F0-8047-4E2E-8350-A25E4043A63C Q43269413-BAD95DD9-197B-46B8-AE05-26224CE44283 Q46000712-011F5099-8668-4E60-84B7-341960081428 Q47096576-548A4541-FC77-4826-9480-D6755D2D3635 Q47144748-1E243B5B-09D3-42A8-A886-DADE98BCFEE3 Q51395627-029C7CC9-E300-4024-AC94-DC776D35CA85 Q51549809-9117A97B-1A70-427B-BBBF-7E6BE507F580

P2860

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

http://www.wikidata.org/entity/Q33862890

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

@ast

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

@en

type

label

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

@ast

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

@en

prefLabel

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

@ast

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

@en

P1433

Q33862890-E723687B-90AC-4824-875A-E35A79077902

P1476

Q33862890-FA970BAA-3E05-4987-B1C6-A90EEA790955

P2093

Q33862890-1309F8CD-A23C-4639-95C8-8C564148A50E

Q33862890-219838A7-3588-42F2-BDD7-339229785394

Q33862890-2742B586-949F-4E8E-9FE1-D790EF56A7C7

Q33862890-315EA7DC-7B78-4C8E-9E2D-AF18A8D5BB95

Q33862890-44DF0C4F-02AC-42EB-928D-2A4CDA728785

Q33862890-4B63B7D3-E122-45C4-ADB4-1F2E137A1AA2

Q33862890-5344733C-5CF9-4143-89DC-597B981FEE24

Q33862890-664A1D8C-799C-414A-A5C0-0B7E225A8ADC

Q33862890-86197E8A-0F99-498F-9F71-AFBED0133198

Q33862890-A8E8C7C7-A122-4D2F-A274-65C79FE3AC38

P2860

Q33862890-13C495C2-5D0E-4DF5-95EF-4CC2DCB5DC1B

Q33862890-25E4159E-4B0F-42C6-8D58-8C809DBBB6D7

Q33862890-25FA1EB5-4CAD-43BC-BDA9-D76B347A438C

Q33862890-267570E0-6B74-4B6B-AF2E-DA130D35B531

Q33862890-2B06DC86-5678-41D6-87E6-5614DA847C21

Q33862890-2B25D8E4-63DB-491C-AC43-B922D5615170

Q33862890-2F344401-3AAD-4E1F-A8F4-AB05E7BC8023

Q33862890-41ADC49F-0B2F-4487-9CBB-D575E10B6524

Q33862890-48DF4CB7-1B3A-4133-AB80-69B5E08A79F3

Q33862890-528146D7-5611-4A7D-8A41-96CD6C880DB2

P304

Q33862890-B7309E97-57FD-4079-9A62-D4DBC7F7266A

P31

Q33862890-1119B65F-CC89-4CBC-93E9-B10FF5F08A6B

P356

Q33862890-3E7BB953-822F-433A-B179-B1ECED651EDC

P433

Q33862890-91129FDC-9613-4314-8633-2160CF46F379

P478

Q33862890-BE00F3D8-E020-4EA8-B888-A07DCA01B440

P50

Q33862890-30E37123-E86B-4920-85FB-5B72DA0E951E

Q33862890-BB1FD541-DD39-4BB7-9567-4DC86DDDA254

Q33862890-C0EA1B8E-57DB-4189-A9D7-47B428CC1090

Q33862890-F64EF927-B56D-458B-BBEA-BE5B2EF480AC

P577

Q33862890-AABEB128-3C23-4E57-8BA1-6D61182FDBFF

P698

Q33862890-F5118114-164E-49C7-A474-548C21E834A0

P932

Q33862890-0A39B363-CFD6-4BA0-BCC6-4D45A4E862EE

P356

1055-9965.EPI-13-0333-T

P1433

Cancer Epidemiology, Biomarkers & Prevention

P1476

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

@en

P2093

G Steven Bova

http://www.w3.org/2001/XMLSchema#string

Hiroyoshi Suzuki

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Takahashi

http://www.w3.org/2001/XMLSchema#string

Katri A Leinonen

http://www.w3.org/2001/XMLSchema#string

Kerri Keiger

http://www.w3.org/2001/XMLSchema#string

Matti Nykter

http://www.w3.org/2001/XMLSchema#string

Shin Egawa

http://www.w3.org/2001/XMLSchema#string

Sung Ho Hahm

http://www.w3.org/2001/XMLSchema#string

Takahiro Kimura

http://www.w3.org/2001/XMLSchema#string

Teemu T Tolonen

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

A transcriptional repressor co-regulatory network governing androgen response in prostate cancers

The role of SPINK1 in ETS rearrangement-negative prostate cancers

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Integrative genomic profiling of human prostate cancer

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.

ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

P304

2333-2344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1055-9965.EPI-13-0333-T

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Tapio Visakorpi

Ulf-Håkan Stenman

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24083995

http://www.w3.org/2001/XMLSchema#string

P932

4086660

http://www.w3.org/2001/XMLSchema#string